{"groups":[{"description":"Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.\n\ncarboplatin: Days -6, -5, -4: 500mg/m2\\^/day intravenously (IV) over 60 minutes\n\netoposide: 600mg/m\\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.\n\nthiotepa: 150mg/m\\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"FG000","title":"2 Transplants"},{"description":"Patients with Germ cell tumors who receive one transplant only.\n\nifosfamide: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\npaclitaxel: 225 mg/m\\^2 intravenous over 3 hours on Day -7.\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nMesna: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"FG001","title":"1 Transplant"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}